New GSK spin-out to develop hearing disorder therapies with £10 million funding
This article was originally published in Scrip
Executive Summary
A £10 million funding round has given rise to Autifony Therapeutics, a spin-out from GlaxoSmithKline that will work on preclinical assets targeting voltage-gated ion channels, to develop treatments for hearing disorders, including noise-induced hearing loss and tinnitus.